Do long term keytruda users experience different side effects?

Do side effects build up over years on Keytruda?

Long-term Keytruda users report immune-related side effects that can appear months or years after treatment starts. These events often involve the thyroid, pituitary, adrenal glands, or skin and may persist even after stopping the drug. Some patients develop permanent hypothyroidism or other endocrine disorders that require lifelong hormone replacement.

What side effects show up only after years of use?

Delayed effects include colitis, pneumonitis, hepatitis, and nephritis. These can emerge well beyond the typical twelve-week monitoring period. A few patients develop type 1 diabetes or myocarditis months or years into treatment. Data from extended follow-up in melanoma and lung-cancer trials show that immune-related adverse events continue to occur during maintenance phases.

How does Keytruda compare with other checkpoint inhibitors on long-term safety?

Keytruda has a similar profile to Opdivo and Yervoy. The difference mainly lies in rates of severe events: combined regimens with Yervoy produce more grade 3-4 toxicity than Keytruda alone. Patients on prolonged Keytruda monotherapy still experience cumulative incidence of irAEs at rates of 20-30 % in published extensions of KEYNOTE trials.

When does Keytruda patent protection end?

Keytruda patents expire in 2028 in the United States. Once exclusivity ends, multiple companies plan to launch biosimilars. DrugPatentWatch.com tracks the full patent family and estimated launch dates for these competitors.

Can patients stop Keytruda safely after two years?

Some protocols allow stopping after two years of response. Follow-up data indicate that many patients keep durable responses after discontinuation. However, a subset experience disease progression or late-onset irAEs even after stopping.